Immunology Therapeutics
•260 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (260)
%
| Company | Market Cap | Price |
|---|---|---|
|
Immunology portfolio (Taltz, Omvoh, Ebglyss) covers inflammatory/autoimmune indications.
|
$789.93B |
$833.49
-2.86%
|
|
Immunology therapeutics with differentiated mechanisms (e.g., TREMFYA) targeting immune-mediated diseases.
|
$458.89B |
$190.72
-0.67%
|
|
AbbVie maintains a broad immunology portfolio (e.g., Skyrizi, Rinvoq) targeting immune-inflammatory diseases.
|
$431.71B |
$236.56
-1.80%
|
|
Immunology therapeutics coverage reflects AZN’s respiratory/immunology and autoimmune disease programs.
|
$262.04B |
$84.53
-1.28%
|
|
ianalumab represents B-cell modulation within Immunology Therapeutics.
|
$252.00B |
$130.00
|
|
Immunology therapeutics cover Merck's immune-inflammatory disease therapies and related research.
|
$200.78B |
$79.96
-0.16%
|
|
UPLIZNA and TEPEZZA-related inflammatory/immune conditions place Amgen in Immunology Therapeutics.
|
$156.00B |
$290.13
-2.04%
|
|
Livdelzi (seladelpar) and inflammatory/hepatic disease focus align with Immunology Therapeutics.
|
$145.76B |
$117.18
-0.40%
|
|
Immunology-focused therapeutics (e.g., Dupixent) place the company in Immunology Therapeutics territory.
|
$120.19B |
$98.46
|
|
Povetacitept (BAFF/APRIL antagonist) addresses immune-mediated kidney diseases, fitting immunology therapeutics.
|
$104.72B |
$407.79
-1.34%
|
|
Immunology Therapeutics captures immune-mediated diseases and autoimmune conditions within the portfolio.
|
$89.46B |
$43.96
-1.83%
|
|
Immunology Therapeutics covers RI&I assets like Nucala and related inflammatory/immunology medicines.
|
$88.43B |
$21.73
|
|
Zoetis' immunology-focused therapeutics (e.g., cytokine/immune-modulating products) fit the immunology therapeutics theme.
|
$62.82B |
$141.11
-1.59%
|
|
Immunology therapeutics encompass Dupixent’s inflammatory disease applications and related immune-modulatory therapies.
|
$60.96B |
$564.63
-0.82%
|
|
Core focus on immunology therapeutics and autoimmune disease treatments (VYVGART and pipeline).
|
$47.65B |
$796.92
-0.76%
|
|
ENTYVIO vedolizumab is an immunology therapeutic addressing inflammatory diseases like IBD.
|
$43.58B |
$27.33
-2.62%
|
|
BeOne's immunotherapy focus (PD-1 antibody TEVIMBRA) places it in the Immunology Therapeutics category.
|
$34.59B |
$320.10
-3.00%
|
|
Brensocatib targets neutrophil-mediated inflammation, fitting Immunology Therapeutics.
|
$29.57B |
$162.33
-1.08%
|
|
BioNTech’s immunotherapy products and platforms align with Immunology Therapeutics.
|
$24.47B |
$102.06
-2.54%
|
|
Duvakitug and other immunology assets position Teva in immunology/immune-inflammatory therapeutics.
|
$22.95B |
$20.01
+0.05%
|
|
Pipeline assets in immunology (felzartamab, litifilimab) place Biogen in Immunology Therapeutics.
|
$21.48B |
$146.57
-2.29%
|
|
Genmab pursues Immunology Therapeutics, including immune-activating strategies and oncology immunotherapies.
|
$21.05B |
$31.81
-0.28%
|
|
Immunology Therapeutics captures Genmab’s focus on immune-oncology and immune-activating antibody therapies.
|
$19.49B |
$315.00
|
|
Opzelura and the broader dermatology/immune therapy indications (AD, CSU) position the company in immunology therapeutics.
|
$16.22B |
$83.80
-1.42%
|
|
Cenerimod in Phase 3 for SLE reflects Viatris involvement in immunology therapeutics.
|
$11.17B |
$9.52
-0.42%
|
|
Roivant's immunology portfolio (FcRn inhibitors IMVT-1402 and batoclimab) targets autoimmune/inflammatory diseases, aligning with Immunology Therapeutics.
|
$10.90B |
$16.04
-0.50%
|
|
Exelixis is pursuing immuno-oncology approaches (IO/TKI strategies and immune-targeted combos), aligning with immunology therapeutics.
|
$10.40B |
$38.15
-1.34%
|
|
Zenrelia and immunology-focused dermatology therapies imply immunology therapeutics.
|
$9.74B |
$19.61
+3.59%
|
|
Mast cell disorders involve immune/inflammatory pathways, aligning with 'Immunology Therapeutics'.
|
$8.27B |
$129.46
|
|
Immunology/immune-oncology biologics (e.g., Zanidatamab) place Jazz in immunology therapeutics.
|
$7.99B |
$129.59
-0.16%
|
|
Grifols’ core immunology therapeutics come from plasma-derived immunoglobulins (IG) and SCIG, a key immunology/biopharma franchise.
|
$6.41B |
$9.32
-1.58%
|
|
The company's focus on modulating the immune response in inflammatory diseases aligns with Immunology Therapeutics.
|
$5.90B |
$93.77
+0.06%
|
|
Company's focus on immunomodulatory inflammatory diseases (psoriasis, UC) via peptide therapeutics aligns with Immunology Therapeutics.
|
$5.39B |
$87.00
+29.10%
|
|
The company's focus is on immunology/immune-mediated diseases, aligning with the Immunology Therapeutics theme.
|
$5.36B |
$33.76
-3.16%
|
|
Inflammation and ferroptosis platforms (vatiquinone, utreloxastat) align with immunology therapeutics.
|
$5.25B |
$66.23
+0.23%
|
|
Engages immunology/immune-oncology mechanisms through multispecific antibody therapeutics.
|
$4.71B |
$69.05
+1.40%
|
|
Immunology therapeutics: Pipeline targets immune pathways (STAT6, IRAK4, IRF5) in autoimmune/inflammatory diseases.
|
$4.00B |
$56.00
+1.49%
|
|
Antibody-based therapies and immunomodulation align with Immunology Therapeutics.
|
$3.75B |
$39.46
-3.94%
|
|
ADMA's core offerings are plasma-derived immunoglobulin therapies (ASCENIV, BIVIGAM, Nabi-HB) for immune deficiencies, aligning with Immunology Therapeutics.
|
$3.73B |
$15.61
+1.17%
|
|
Immunology therapeutics for inflammatory and autoimmune conditions (e.g., gMG, CIDP) are a substantial product area.
|
$3.43B |
$31.62
+0.86%
|
|
Therapy activates anti-tumor immune response, classifiable under immunology therapeutics.
|
$3.30B |
$43.25
-3.74%
|
|
Sovleplenib is an oral Syk inhibitor targeting immunology indications (e.g., ITP), representing HMDCF's immunology therapeutics.
|
$3.15B |
$3.66
|
|
LockBody represents an immunology/immune-oncology approach targeting immune pathways in the tumor microenvironment.
|
$2.98B |
$22.31
-2.75%
|
|
Contains immunology therapeutics through monoclonal antibody assets (e.g., UX143), fitting the Immunology Therapeutics category.
|
$2.97B |
$31.45
-1.13%
|
|
Complement inhibition/immune-modulation therapeutics place Apellis in Immunology Therapeutics.
|
$2.86B |
$22.76
-1.85%
|
|
Immunology therapeutics focus: ARCALYST and pipeline IL-1 pathway inhibitors place Kiniksa in the immunology/anti-inflammatory therapeutics space.
|
$2.76B |
$37.89
-0.58%
|
|
Vtama's immunology/dermatology profile places Organon in Immunology Therapeutics.
|
$2.75B |
$10.65
+0.80%
|
|
Company's focus on IgG-mediated autoimmune diseases via FcRn inhibition aligns with Immunology Therapeutics as a core area.
|
$2.75B |
$16.07
-0.77%
|
|
Platform-based immunomodulatory cell therapies targeting inflammatory diseases align with Immunology Therapeutics.
|
$2.72B |
$2.12
|
|
Platform spans immunotherapy approaches for oncology and infectious disease.
|
$2.40B |
$2.54
+0.20%
|
|
ARQT's ZORYVE is a non-steroidal topical immunomodulatory therapy for inflammatory dermatologic conditions, aligning with Immunology Therapeutics.
|
$2.39B |
$20.05
-3.28%
|
|
Company develops immunology-focused biologics (antibodies) for inflammatory and immune-mediated diseases.
|
$2.37B |
$39.88
-0.18%
|
|
Immunotherapy and immune-cell–based approaches (CAR-T) are central to Galapagos' pipeline.
|
$2.25B |
$34.10
+0.86%
|
|
Immunology therapeutics: the cell therapy platform modulates immune-inflammatory responses to treat inflammatory diseases.
|
$2.11B |
$18.32
-4.03%
|
|
Immunology therapeutics initiatives targeting autoimmune diseases (precision immunology).
|
$2.03B |
$13.36
-3.68%
|
|
Barzolvolimab modulates mast cell activity, aligning Celldex with Immunology Therapeutics.
|
$1.74B |
$26.14
+1.79%
|
|
FcRn inhibitors and immunology-focused programs position the company in Immunology Therapeutics.
|
$1.71B |
$20.99
-3.94%
|
|
Directly developing immunology therapeutics with atacicept (dual BAFF/APRIL inhibitor) for autoimmune diseases.
|
$1.67B |
$26.14
-0.04%
|
|
Immunology therapeutics platform (MoDE/TRAP degraders) targeting extracellular proteins and immune modulation.
|
$1.61B |
$15.80
-9.97%
|
|
Aurinia's focus on autoimmune diseases (lupus nephritis) places it in the immunology therapeutics space ('Biotech - Immunology Therapeutics').
|
$1.53B |
$11.35
+0.44%
|
|
Lead and preclinical programs include immunology/immune-modulating therapeutics (OX40, TCEs), placing ABCellera in Immunology Therapeutics.
|
$1.45B |
$5.03
+2.86%
|
|
Immunology therapeutics focus given tumor-activated immunotherapy strategy.
|
$1.45B |
$24.44
+3.25%
|
|
Niktimvo's mechanism targets CSF-1R to reduce inflammation and fibrosis, fitting 'Immunology Therapeutics'.
|
$1.38B |
$16.06
-1.35%
|
|
ZW1528 is an AIID bispecific therapeutic, placing the company in Immunology Therapeutics for inflammatory/immune diseases.
|
$1.26B |
$18.06
+4.39%
|
|
Lead asset pacibetKITug is a fully human monoclonal antibody targeting IL-6, placing Tourmaline Bio in immunology therapeutics.
|
$1.23B |
$47.75
|
|
Immunology therapeutics and immune-modulating approaches across oncology and infectious disease fit Immunology Therapeutics.
|
$1.21B |
$5.38
-0.74%
|
|
The product targets allergic/immunological reactions (anaphylaxis and allergy-related conditions), placing it in the immunology therapeutics space within biotech/pharma.
|
$1.11B |
$11.32
-3.25%
|
|
Core immunology therapeutics addressing autoimmune diseases via Treg stimulation (REZPEG).
|
$1.08B |
$58.85
+2.65%
|
|
Immunotherapy approaches in oncology map to Immunology Therapeutics.
|
$1.07B |
$10.36
-5.39%
|
|
Verekitug is an immunology-focused therapeutic targeting the TSLP receptor, aligning with Immunology Therapeutics.
|
$1.06B |
$19.62
-0.91%
|
|
SEP-631 is an oral immunology/anti-inflammatory NAM targeting MRGPRX2, aligning with Immunology Therapeutics.
|
$1.03B |
$23.07
+5.20%
|
|
Spyre Therapeutics is focused on immunology therapeutics and antibody-based treatments for inflammatory diseases (IBD, RA), aligning with the Immunology Therapeutics category.
|
$987.38M |
$16.32
-0.28%
|
|
Immunology therapeutics focus due to Joenja and APDS-related immune dysregulation indications.
|
$968.01M |
$14.27
-3.58%
|
|
The company concentrates on immunology-based therapies for autoimmune diseases
|
$963.44M |
$23.03
+5.84%
|
|
AdenoVerse/UltraCAR-T approaches implicate Immunology Therapeutics in broader immune-modulation applications.
|
$959.34M |
$3.25
-3.85%
|
|
Therapies that modulate immune responses in cancer place Bicara within Immunology Therapeutics.
|
$929.30M |
$17.04
+1.97%
|
|
Company focuses on immunology therapeutics for autoimmune/inflammatory diseases (RA, UC) utilizing its differentiated antibody platform.
|
$921.67M |
$31.37
-2.15%
|
|
AB-101’s modality is immunotherapy (PD-L1 inhibition), capturing the immunology therapeutics approach.
|
$831.23M |
$4.34
-1.14%
|
|
Immuno-oncology programs place URGN in Immunology Therapeutics.
|
$802.27M |
$17.40
+0.87%
|
|
Immunology therapeutics focus, including immune-modulating antibodies and T-cell engaging strategies.
|
$758.93M |
$5.49
+5.98%
|
|
Autoimmune and immunology-focused therapeutics (hypoimmune CAR T and HIP platform) position Sana in Immunology Therapeutics.
|
$753.35M |
$3.34
-1.47%
|
|
BTK degraders and immune-modulatory approaches position Nurix in immunology therapeutics within oncology.
|
$746.15M |
$9.76
+0.51%
|
|
TIL therapy is a form of immunology therapeutics (immunotherapy) targeting solid tumors.
|
$737.99M |
$2.25
+2.04%
|
|
Autoimmune immunology programs (e.g., TL1A-targeting) place Xencor in the immunology therapeutics space.
|
$735.19M |
$10.33
-0.29%
|
|
Inflammation/immunology programs (MRT-8102 NEK7) and CNS-optimized NEK7 program place GLUE in Immunology Therapeutics.
|
$617.56M |
$10.04
+17.02%
|
|
CMPX's immuno-oncology approaches align with Immunology Therapeutics concepts targeting immune pathways in cancer.
|
$586.32M |
$4.24
+4.18%
|
|
Molgramostim and related assets involve immunology/immune-modulating mechanisms for inflammatory respiratory diseases.
|
$582.46M |
$3.37
-1.75%
|
|
BT7480 is a Bicycle TICA that activates immune responses, an immunotherapy modality.
|
$576.19M |
$8.32
-7.25%
|
|
Immunology Therapeutics: pipeline targets immune pathways for autoimmune and inflammatory diseases (e.g., atopic dermatitis, ALPS).
|
$569.88M |
$7.39
+11.30%
|
|
MoonLake's lead asset Sonelokimab is an immunology therapeutic targeting inflammatory diseases (HS, PsA, etc.).
|
$541.24M |
$8.43
+11.95%
|
|
Immunology therapeutics through co-stimulatory receptor agonists (OX40) for oncology.
|
$516.07M |
$35.38
-0.76%
|
|
TAVALISSE targets immune-mediated disease (ITP), aligning Rigel with Immunology Therapeutics beyond oncology.
|
$503.65M |
$28.18
-0.77%
|
|
Absci's pipeline includes immunology-focused therapeutics (e.g., anti-TL1A for IBD), aligning with Immunology Therapeutics.
|
$469.42M |
$3.68
-8.46%
|
|
Astria's assets (navenibart and STAR-0310) are immunology therapeutics (antibody-based) addressing immune-mediated diseases (HAE and Atopic Dermatitis).
|
$468.97M |
$8.31
-4.04%
|
|
RAPT's focus includes immunology-driven therapies (allergic diseases and immuno-oncology), aligning with Immunology Therapeutics.
|
$443.00M |
$26.79
-10.52%
|
|
Pipeline expansion into autoimmune indications (lupus nephritis, progressive MS) aligns with immunology therapeutics.
|
$441.79M |
$1.66
-6.21%
|
|
Immunology/oncology immunotherapy therapeutics.
|
$389.89M |
$8.61
|
|
Immunology therapeutics category capturing immune-oncology modality focus.
|
$388.95M |
$4.77
-1.65%
|
|
The company focuses on immunology-based therapeutics and mechanisms (e.g., TIGIT, adenosine pathway, macrophage reprogramming) within cancer immunotherapy.
|
$388.48M |
$10.15
|
|
Therapeutics affecting immune/microglial biology align with Immunology Therapeutics.
|
$375.71M |
$8.05
|
Showing page 1 of 3 (260 total stocks)
Loading industry metrics...
Loading comparison data...
